ADARx Prices Upsized IPO for Expected $446.3 Million in Gross Proceeds

Key Facts

ADARx Pharmaceuticals priced its upsized initial public offering at $17.00 a share, for expected gross proceeds of about $446.3 million before underwriting fees and expenses. The company is selling 26.25 million common shares, so the anticipated proceeds will go to ADARx before transaction costs are deducted. Trading is scheduled to begin on the Nasdaq Global Select Market under the ticker ADRX on September 25, 2026. The offer price gives investors an initial reference point for valuation, but it does not determine the price formed when trading starts. After listing, investors will weigh that price against the company's ability to turn new funding into measurable clinical progress.

The final offer is larger than the plan in ADARx's September 21, 2026 preliminary prospectus, which proposed 21.875 million shares at $15 to $17 each. The final $17.00 price sits at the top of that range, while the share count increased by 4.375 million. The larger transaction therefore reflects two separate changes: more shares for sale and pricing at the range's upper end. That comparison explains the move from the preliminary plan to the final terms more clearly than the headline proceeds figure alone. It also matters to prospective holders because the number of new shares affects the ownership represented by each share after the offering.

The $446.3 million figure is expected gross proceeds from the base offering, rather than the full amount available for clinical spending. Underwriting discounts, commissions and company-paid offering expenses must be deducted before the cash addition can be assessed. The underwriters also have a 30-day option to buy as many as 3.9375 million additional shares at the public price, less underwriting discounts and commissions. Exercising that option would increase both funding and shares outstanding; its potential proceeds are excluded from the announced $446.3 million. Keeping the base sale separate from the option gives investors a clearer view of the transaction's possible effects on cash and ownership.

The financing package includes a separate, concurrent private placement to AbbVie at $17.00 a share, according to ADARx's announcement. AbbVie has agreed to buy enough shares to own about 4.9% of those outstanding after both transactions close, subject to a $100 million purchase cap. ADARx expects combined gross proceeds of about $535.2 million before expenses, excluding any exercise of the underwriters' option. The private placement depends on the IPO closing, while the IPO does not depend on the private placement, a distinction when assessing conditional funding. AbbVie's prospective stake also gives its research partner direct exposure to ADARx's market value without guaranteeing clinical success.

ADARx develops siRNA therapies designed to reduce production of proteins involved in specific diseases, and its pipeline spans several clinical stages. Its most advanced program, onvuzosiran, is being tested to prevent hereditary angioedema attacks in the Phase 3 STOP-HAE trial. The company is studying agazisiran in Phase 2 trials for complement-mediated diseases and developing ADX-626, a Factor XI-targeting program for stroke prevention. Those stages explain why trial funding matters to the stock: studies must establish safety and efficacy before a treatment can seek approval. ADARx has no product approved for sale and has generated no drug-sales revenue, leaving clinical results central to its valuation.

The preliminary prospectus sets out planned uses for existing resources together with proceeds from the IPO and AbbVie placement, including about $180 million for agazisiran. ADARx plans to allocate about $65 million to onvuzosiran, including completion of STOP-HAE and activities ahead of possible commercialization. Its plan assigns about $80 million to ADX-626, including completion of Phase 1 and advancement toward later stroke-prevention studies. It also assigns about $25 million to ADX-077 and $20 million to ADX-199, with the remainder for research, working capital and general corporate purposes. Spending is spread across several programs, and its timing will depend on trial progress and costs.

ADARx held about $427.3 million in cash, cash equivalents and short-term investments as of June 30, 2026, the preliminary prospectus shows. That balance is the starting point for judging how long operations can be funded after net transaction proceeds are added; gross proceeds alone are insufficient. The company says those existing resources plus expected net IPO and private-placement proceeds should cover planned operating and capital needs into 2030. Its estimate depends on assumptions about the pace and cost of development and could change if programs accelerate or unforeseen expenses arise. Investors can assess the financing by how far it carries the company toward forthcoming study results without another near-term capital raise.

Research and development spending rose to $48.3 million in the six months ended June 30, 2026, from about $30.0 million a year earlier, according to the prospectus. The net loss for the same period widened to $48.4 million from $33.6 million, illustrating the cost of expanding work before drug sales begin. Research spending is an ongoing use of cash, whereas IPO proceeds add financing when the transaction closes. Comparing the offering amount with one period's loss therefore does not establish a fixed funding runway, because expenses change as trials grow. Future research spending will help show whether the company's current estimate of cash sufficiency remains plausible.

AbbVie also has a research collaboration and license option agreement with ADARx, signed in May 2025, under which ADARx received a $335 million upfront payment. ADARx treats that payment as deferred revenue to be recognized over later periods under the collaboration, rather than revenue from an approved medicine. Collaboration revenue was about $2.9 million in the first half of 2026, compared with about $0.2 million a year earlier. That revenue should be distinguished from the proposed AbbVie share purchase: one arises from an existing research contract, while the other would add equity capital. The distinction makes both the company's earnings and sources of cash easier to interpret at its market debut.

For a buyer of ADRX, the $17.00 offer price is the entry price for IPO participants; subsequent market prices will be set by trading. The preliminary offer covered 21.875 million shares, rising to 26.25 million at pricing and increasing the number of new shares sharing the company's value. AbbVie's private placement would add more shares if it closes, and the underwriters' option could add another block. Assessing a potential return therefore requires weighing additional cash against the larger share count and the chance that funded trials succeed. The principal risk is that clinical spending could rise or results be delayed without enough therapeutic progress to support the valuation.

ADARx expects the IPO and concurrent private placement to close on September 28, 2026, subject to customary conditions for each transaction. After ADRX trading is scheduled to start on September 25, the first direct market comparison will be between its trading price and the $17.00 offer price. For its pipeline, ADARx expects initial agazisiran study data from mid-2027 through its second half and STOP-HAE topline results by the end of 2027. If STOP-HAE results are positive, the company anticipates a possible drug application in 2028, a conditional plan rather than regulatory approval. The closings, market debut and subsequent trial readouts will show whether the larger financing is accompanied by clinical progress that supports the stock.